Daiichi Sankyo’s Savaysa Gets U.S. OK, With Limitations
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo has won approval from the U.S. FDA to market Savaysa (edoxaban), an oral factor Xa inhibitor, as a treatment to reduce the risk of stroke and systemic embolism events in patients with nonvalvular atrial fibrillation (NVAF), although US regulators set some limitations on that indication.